Parallax Volatility Advisers, L.P. Aravive, Inc. Transaction History

Parallax Volatility Advisers, L.P.

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2019 Aug 14, 2019	SELL	$5.65 - $7.5 $33,097 - $43,935	-5,858 Reduced 54.85%	4,823 $29,000
Q1 2019 May 15, 2019	BUY	$3.35 - $8.27 $35,781 - $88,331	10,681 New	10,681 $75,000

28.1K

Ticker ARAV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,518,300
Description
Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of pl...

Get notified when there are updates to the investment portfolio of Parallax Volatility Advisers, L.P., based on Form 13F filings with the SEC.

Stay updated on Parallax Volatility Advisers, L.P. with notifications on news.